<DOC>
	<DOCNO>NCT00003341</DOCNO>
	<brief_summary>RATIONALE : Drugs epoetin alfa may relieve anemia cause chemotherapy . The best time give epoetin alfa chemotherapy yet know . PURPOSE : Randomized phase III trial study effectiveness epoetin alfa treat anemia patient lymphoma , chronic lymphocytic leukemia , multiple myeloma receive chemotherapy .</brief_summary>
	<brief_title>Epoetin Alfa Treating Anemia Patients With Lymphoma , Chronic Lymphocytic Leukemia , Multiple Myeloma Anemia Caused By Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine hematologic response transfusion requirement patient malignant lymphoma , chronic lymphocytic leukemia , multiple myeloma chemotherapy relate moderate anemia treat epoetin alfa . - Determine effect moderate anemia quality life patient treat regimen . - Correlate change quality life change anemia associate treatment epoetin alfa patient . - Determine effect change quality life health care resource utilization among patient treat epoetin alfa . OUTLINE : This randomize , open label , multicenter study . Patients evaluate anemia prescribed chemotherapy regimens either 3 4 week interval begin week 3 4 . Patients hemoglobin level 10.0-12.0 g/dL randomize 1 2 treatment arm . Patients hemoglobin level great 12.0 g/dL randomize hemoglobin level decrease 12.0 g/dL . - Arm I : Patients immediately receive epoetin alfa subcutaneously week . - Arm II : Patients observe 6-8 week hemoglobin level reevaluate . Patients whose hemoglobin level decrease 9.0 g/dL receive epoetin alfa subcutaneously week . Patients whose hemoglobin level least 9.0 g/dL observe another 3-4 week hemoglobin level reevaluate . Patients receive epoetin alfa treatment 15 16 week . Qualify life questionnaire complete every 3 4 week week 30 32 . Patients follow week 36 . PROJECTED ACCRUAL : A total 275 patient ( least 130 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma ( NHL ) , chronic lymphocytic leukemia , multiple myeloma Low grade , intermediate grade , high grade ( diffuse large cell immunoblastic ) NHL OR Histologically confirm Hodgkin 's disease prior chemotherapy Evaluable lesion Must schedule least 1 myelosuppressive cytotoxic regimen ( experimental chemotherapy regimen allow ) least 46 month No anemia predominantly due factor cancer chemotherapy ( i.e. , iron folate deficiency , hemolysis , gastrointestinal bleeding ) NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : Transferrin saturation least 20 % Ferritin least 50 ng/mL OR Adequate iron store bone marrow If transferrin saturation le 20 % ferritin le 50 ng/mL , investigator may utilize bone marrow evaluation result determine whether iron store adequate Hemoglobin least 10.0 g/dL Hepatic : Not specify Renal : Not specify Cardiovascular : No uncontrolled hypertension Other : HIV negative No active , unresolved infection No hypersensitivity mammalian cell derive product Must able read understand English 6th grade level consistent comprehending quality life questionnaires No malignancy within past 5 year , except basal cell skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent epoetin alfa independent protocol No concurrent interferon interleukin ( occasional short term use may permit case case basis ) No prior peripheral blood stem cell transplantation Chemotherapy : See Disease Characteristics At least 2 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior total lymphoid , extensive abdominal , invert Y radiotherapy Surgery : Not specify Other : At least 30 day since prior nonchemotherapy experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>anemia</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>